RX Biosyent Inc

BioSyent Inc. ("BioSyent", the "Company")(TSX VENTURE:RX) today released its
second quarter 2007 financial results. Sales for the six months ended June 30,
2007 were $447,946, an increase of 8% versus $413,364 in the same period in
2006. The increase in sales was mainly due to an increase in Canadian orders for
Protect-It(R). While FeraMAX(TM) shipments to wholesale customers commenced in
Q2, these were primarily initial stocking orders as one strength of FeraMAX(TM)
was not available until late in the quarter. The first six month sales increase
coupled with a 2.6% improvement in product margin, increased gross profit by
13%, from $260,863 in the first six months of 2006 to $294,110 in the first six
months of 2007.


During the first six months of 2007 promotion of FeraMAX(TM) was escalated.
Increased investments made in sales force and other product promotion increased
operating expenses for the six months ended June 30, 2007 to $489,594 (2006 -
$282,080). In addition to FeraMAX(TM) promotion, the first six months of 2007
operating expenses also included $37,205 of non-cash expenses for stock-based
(share options) compensation and foreign exchange adjustments.


The net loss for the first six months of 2007 was $177,374, compared to a net
loss of $7,099 in the same period in 2006. This translates to a loss per share
of $0.014 (1.4 cents per share) for the six months ended June 30, 2007. As at
June 30, 2007 the Company had working capital of $1,043,930 (including cash and
cash equivalents of $985,103).


BioSyent continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024